Table 1.
Baseline demographics and disease characteristics of patients receiving at least second-line therapy for adv/met ESCC, stratified by 2L taxane groupings
| All ≥ 2L patients (n = 86) | 2L taxane therapy (n = 37) | 2L non-taxane therapy (n = 49) | |
|---|---|---|---|
| Median (range) age at index, years | 64 (36–83) | 63 (36–81) | 65 (37–83) |
| Age group at index, n (%) | |||
| < 65 years | 45 (52.3) | 21 (56.8) | 24 (49.0) |
| ≥ 65 years | 41 (47.7) | 16 (43.2) | 25 (51.0) |
| Male, n (%) | 61 (70.9) | 29 (78.4) | 32 (65.3) |
| Race, n (%) | |||
| White | 52 (60.5) | 22 (59.5) | 30 (61.2) |
| Black or African American | 14 (16.3) | 7 (18.9) | 7 (14.3) |
| Asian | 6 (7.0) | 2 (5.4) | 4 (8.2) |
| Other race | 9 (10.5) | 4 (10.8) | 5 (10.2) |
| Missing | 5 (5.8) | 2 (5.4) | 3 (6.1) |
| Geographic region, n (%) | |||
| South | 37 (43.0) | 18 (48.6) | 19 (38.8) |
| Northeast | 22 (25.6) | 7 (18.9) | 15 (30.6) |
| West | 12 (14.0) | 5 (13.5) | 7 (14.3) |
| Midwest | 10 (11.6) | 3 (8.1) | 7 (14.3) |
| Unknown | 3 (3.5) | 2 (5.4) | 1 (2.0) |
| Other regions | 2 (2.3) | 2 (5.4) | 0 |
| Benefit plan type at indexa, n (%) | |||
| Commercial health plan | 25 (29.1) | 11 (29.7) | 14 (28.6) |
| Other payer (unknown) | 21 (24.4) | 11 (29.7) | 10 (20.4) |
| Medicare | 19 (22.1) | 7 (18.9) | 12 (24.5) |
| Medicaid | 6 (7.0) | 4 (10.8) | 2 (4.1) |
| Other government | 3 (3.5) | 1 (2.7) | 2 (4.1) |
| Patient assistance | 1 (1.2) | 0 | 1 (2.0) |
| Self-pay | 1 (1.2) | 1 (2.7) | 0 |
| Missing | 27 (31.4) | 8 (21.6) | 19 (38.8) |
| Practice type, n (%) | |||
| Community | 83 (96.5) | 35 (94.6) | 48 (98.0) |
| Academic | 3 (3.5) | 2 (5.4) | 1 (2.0) |
| Disease stage at initial diagnosis, n (%) | |||
| Stage I | 5 (5.8) | 2 (5.4) | 3 (6.1) |
| Stage II | 7 (8.1) | 5 (13.5) | 2 (4.1) |
| Stage III | 9 (10.5) | 3 (8.1) | 6 (12.2) |
| Stage IV | 62 (72.1) | 25 (67.6) | 37 (75.5) |
| Unknown | 3 (3.5) | 2 (5.4) | 1 (2.0) |
| ECOG at start of 2Lb, n (%) | |||
| Data available | 53 (61.6) | 21 (57) | 32 (65.3) |
| 0 | 21 (39.6) | 6 (28.6) | 15 (46.9) |
| 1 | 19 (35.8) | 10 (47.6) | 9 (28.1) |
| 2 | 10 (18.9) | 5 (23.8) | 5 (15.6) |
| 3 | 3 (5.7) | 0 | 3 (9.4) |
| Data not available | 33 (38.4) | 16 (43) | 17 (34.7) |
Adv/met unresectable locally advanced, recurrent or metastatic, EC esophageal cancer, ECOG PS Eastern Cooperative Oncology Group performance score, SD standard deviation
aPatients could be enrolled in more than one insurance provider type
bClosest ECOG value on or before start of second-line treatment